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OBJECTIVE
Evaluate the efficacy and safety of the dual sodium–glucose cotransporter 1 (SGLT1)
and SGLT2 inhibitor sotagliflozin in combination with optimized insulin in type 1
diabetes (T1D).
RESEARCH DESIGN AND METHODS
The inTandem1 trial, a double-blind, 52-week phase 3 trial, randomized North
American adults with T1D to placebo (n = 268), sotagliflozin 200 mg (n = 263), or
sotagliflozin 400mg (n = 262) after 6weeks of insulin optimization. The primary end
point was HbA1c change from baseline at 24 weeks. HbA1c, weight, and safety were
also assessed through 52 weeks.
RESULTS
From amean baseline of 7.57%, placebo-adjusted HbA1c reductions were 0.36% and
0.41% with sotagliflozin 200 and 400 mg, respectively, at 24 weeks and 0.25% and
0.31% at 52 weeks (all P < 0.001). Among patients with a baseline HbA1c ‡7.0%, an
HbA1c <7% was achieved by 15.7%, 27.2%, and 40.3% of patients receiving placebo,
sotagliflozin 200mg, and sotagliflozin 400mg, respectively (P £ 0.003 vs. placebo) at
24 weeks. At 52 weeks, mean treatment differences between sotagliflozin 400 mg
and placebo were21.08 mmol/L for fasting plasma glucose,24.32 kg for weight,
and 215.63% for bolus insulin dose and 211.87% for basal insulin dose (all P <
0.001). Diabetes Treatment Satisfaction Questionnaire scores increased significantly
by 2.5 points with sotagliflozin versus placebo (P < 0.001) at 24 weeks. Genital
mycotic infections and diarrhea occurred more frequently with sotagliflozin.
Adjudicated diabetic ketoacidosis (DKA) occurred in 9 (3.4%) and 11 (4.2%) patients
receiving sotagliflozin 200 and 400 mg, respectively, and in 1 (0.4%) receiving
placebo. Severe hypoglycemia occurred in 17 (6.5%) patients from each sotagliflozin
group and 26 (9.7%) patients receiving placebo.
CONCLUSIONS
In a 1-year T1D study, sotagliflozin combined with optimized insulin therapy was
associated with sustained HbA1c reduction, weight loss, lower insulin dose, fewer
episodes of severe hypoglycemia, improved patient-reported outcomes, and more
DKA relative to placebo (ClinicalTrials.gov, NCT02384941).
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Achieving glycemic targets is difficult
for patients with type 1 diabetes (T1D);
hypoglycemia, wide glucose fluctuations,
and weight gain represent major unre-
solved challenges (1–6) that threaten
patient health (7,8). Mitigating these
side effects is essential in T1D manage-
ment. Pramlintide is approved as an
insulin adjunct and may reduce weight
as well as HbA1c, but it requires multiple
additional daily injections and is associ-
ated with an increased risk of severe
hypoglycemia (1,2,9). Agents from other
antihyperglycemic classes have not de-
monstrated sufficient benefit in T1D
for manufacturers to pursue market au-
thorization (10–13). Combining insulin
with oral sodium–glucose cotransporter
(SGLT) inhibitors holds promise to im-
prove glycemic control in T1D without
increasing weight or hypoglycemia, and
an agent that inhibits SGLT1 further
contributes to a blunting and delay
of postprandial hyperglycemia (14–16).
However, diabetic ketoacidosis (DKA)
has emerged as the major clinical con-
cern around SGLT inhibition in T1D
(17,18). Possible contributors include
decreased basal insulin, a shift to fatty
acid oxidation, and increased urinary glu-
cose excretion and volume depletion as-
sociated with SGLT2 inhibition (19,20).
Sotagliflozin (LX4211) is a novel dual
inhibitor of SGLT1 and SGLT2 that
decreases renal glucose reabsorption
through systemic SGLT2 inhibition and
delays and reduces glucose absorption
in the proximal intestine through local
SGLT1 inhibition, blunting and delay-
ing postprandial hyperglycemia (21–23).
Dual inhibition of SGLT1 and SGLT2
may mitigate DKA risk by reducing glu-
cose absorption in the proximal intestine
and thereby diminishing urine glucose
excretion and associated water and elec-
trolyte loss; by increasing glucagon-like
peptide 1 secretion from the gut, thereby
reducing glucagon; and by preserving
basal insulin requirements (24–28). We
report the efficacy and safety of sotagli-
flozin combined with insulin delivered
as multiple daily injections (MDI) or con-
tinuous subcutaneous insulin infusion
(CSII) in North American adults with
T1D.
RESEARCH DESIGN AND METHODS
Design Overview
This phase 3, multicenter, random-
ized, double-blind, placebo-controlled,
parallel-group study conducted at 75
sites in the U.S. and Canada evaluated
the safety and efficacy of oral sotagli-
flozin 200 or 400 mg combined with
insulin in adult patients with inade-
quately controlled T1D. The study con-
sisted of two double-blind periods: a
24-week treatment period (the primary
end point assessment) followed by a
28-week double-blind extension (Fig.
1). Randomization was stratified by in-
sulin delivery method (MDI or CSII), and
week22 HbA1c values (#8.5%,.8.5%).
A subgroup of patients underwent
blinded continuous glucose monitoring
(CGM) with a Dexcom G4 monitor (Dex-
com, San Diego, CA) during specified
1-week intervals throughout the first
24 weeks.
Starting 6 weeks before randomiza-
tion, insulin therapy was optimized by
adjusting basal and bolus doses to main-
tain fasting or preprandial blood glucose
between 4.4 and 7.2 mmol/L (80 and
130 mg/dL) and 1- to 2-h postprandial
glucose ,10 mmol/L (,180 mg/dL). In-
sulin adjustment continued throughout
the trial (Fig. 1).
Institutional review boards approved
the protocol and consent forms. All
patients provided written informed con-
sent. An independent clinical end point
committee, blinded to trial treatment,
adjudicated severe hypoglycemia, DKA,
major adverse cardiovascular events,
drug-induced liver injury, and deaths.
An independent insulin dose monitoring
committee (IDMC) comprising diabetol-
ogists and certified diabetes educators
blindly reviewed insulin titration deci-
sions from the start of insulin optimiza-
tion (6 weeks before baseline) through
week 24 to determine whether insulin
adjustments were consistent with self-
monitoring of blood glucose (SMBG)
patterns. An independent data moni-
toring committee reviewed safety. An
independent statistician performed sta-
tistical analysis.
Study Population
The study included men and nonpreg-
nant women aged $18 years with
T1D using either MDI or CSII for insulin
delivery and whose HbA1c was 7.0–
11.0% at screening. Patients with
b-hydroxybutyrate (BHB) levels .0.6
mmol/L at screening were excluded.
The Supplementary Data lists all inclusion
and exclusion criteria.
Figure 1—Study design. After a 2-week screening period, insulin therapywas optimized for 6weeks
prior to randomization (R), and optimized insulin continued until the study conclusion at week 52.
After a 2-week placebo run-in, patients were randomly assigned to double-blind (DB) treatment
with sotagliflozin 200 or 400 mg or placebo for 52 weeks. Insulin optimization refers to the
adjustment of insulin to meet standard-of-care glycemic targets starting 6 weeks prior to
randomization, which continued for the entire study. An IDMC assessed standard-of-care
adherence and provided feedback to the principal investigator if deviations from standard of
care were observed prior to week 24; HbA1c was masked to study staff during this period. Between
week 24 and 52, insulin optimization continued without input from the IDMC, and HbA1c values
were unmasked. Safety was monitored for 30 days after the last dose of study medication.
Interventions
Patients were randomly assigned 1:1:1
to sotagliflozin 200 mg, sotagliflozin 400
mg, or placebo administered once daily
before the first meal of the day. Bolus
insulin was reduced by 30% for the first
meal after the first dose of study med-
ication on day 1 only (24). Thereafter and
throughout the 52-week study, investi-
gators and/or patients adjusted insulin
doses according to SMBG data to meet
study targets. Based on regulatory feed-
back, HbA1c and fasting plasma glucose
(FPG) results were masked to study staff
from baseline to week 24. After week
12, HbA1c .11% was unmasked to
allow appropriate intervention. During
the 28-week extension period, HbA1c and
FPG were unmasked. All patients re-
ceived urine ketone strips and BHB me-
ters and strips as well as instructions on
detecting and treating ketosis (Supple-
mentary Data), urogenital hygiene, and
proper hydration. Study centers received
recommendations for ketosis and DKA
diagnosis and management (Supplemen-
tary Data).
End Points
The primary end point was the change in
HbA1c from baseline to week 24. The first
secondary end point was a composite
consisting of the proportion of patients
with HbA1c,7.0% who had no episode of
severe hypoglycemia and no episode of
DKA at week 24. Other secondary out-
comes included the change from base-
line to week 24 in body weight, bolus
insulin dose, FPG, and scores on the
Diabetes Treatment Satisfaction Ques-
tionnaire Status (DTSQs) and the 2-item
Diabetes Distress Screening Scale (DDS2)
(29,30). Additional objectives included the
change from baseline in systolic blood
pressure (SBP) and diastolic blood pres-
sure at week 12 in all patients and SBP in
those with SBP $130 mmHg at base-
line. HbA1c, FPG, insulin dose, weight,
frequency of documented hypoglycemic
events (#3.9 and #3.0 mmol/L [#70
and #55 mg/dL], measured by SMBG),
and kidney function were assessed at
each study visit throughout the 52-week
study. Prespecified composite end points
included the proportions of patients
meeting HbA1c targets (,7.0% or $0.5%
reduction) without experiencing severe
hypoglycemia, DKA, or weight gain at
24 and 52 weeks. Safety and tolerability
were evaluated throughout the study.
DKA diagnosis was based on evidence of
metabolic acidosis and other criteria (see
Supplementary Data for details).
Statistical Methods
Efficacy analyses were based on the
modified intent-to-treat population,
which included all randomized patients
who had taken at least one dose of study
drug. The primary efficacy end point was
the main driver used to calculate the
sample size, and the latter was derived by
specifying a treatment difference to de-
tect between either dose level of sotagli-
flozin versus placebo of at least 20.4%
and a common SD of this difference as
1.0%. The statistical testing method was
planned to control the type 1 family-wise
error rate both within and across the
primary and secondary end points at a =
0.05. Targeting a statistical power of
$90% to detect the stated difference
and adjusting for dropouts, 250 patients
per treatment group was the estimated
sample size requirement. Primary effi-
cacy end point data were analyzed using
mixed-effects model for repeated mea-
sures (MMRM) statistics based on the
restricted maximum likelihood method
for estimation. The analysis model in-
cluded fixed categorical effects of treat-
ment, randomization strata based on use
of MDI or CSII, HbA1c #8.5% or .8.5%
at week 22, and other covariates. For
continuous secondary and other efficacy
end points, MMRM or ANCOVA was
used, with the corresponding end point
and baseline value (including first-order
interactions in theMMRM) in themodel.
Forbinaryendpoints, a Cochran–Mantel–
Haenszel test, stratified by the random-
ization stratification factors, was used.
The treatment group comparisons were
performed at week 24, with descriptive
statistics provided for each clinic visit
through week 52. Missing observations
at week 24 were imputed as nonresponse.
See Supplementary Data for additional
details.
RESULTS
Between March 2015 and February 2017,
793 patients were randomly assigned
to treatment with placebo (n = 268),
sotagliflozin 200 mg (n = 263), or
sotagliflozin 400 mg (n = 262), and 218,
228, and 221 completed the study, re-
spectively (Supplementary Fig. 1). Base-
line characteristics were similar among
groups (Supplementary Table 1). In the
total cohort, 473 (59.6%) patients used
CSII and 320 (40.4%) used MDI, with
similar proportions in each treatment
group (Supplementary Table 1).
Glycemic Control
Insulin optimization over 6 weeks im-
proved HbA1c by ;0.65% in the three
treatment groups, lowering the mean
HbA1c from ;8.2% (66 mmol/mol) at
screening to 7.54% (58.9 mmol/mol),
7.61% (59.7 mmol/mol), and 7.56%
(59.1 mmol/mol), in the placebo,
sotagliflozin 200 mg, and sotagliflozin
400 mg groups, respectively, at random-
ization (baseline). At the week 24 primary
end point assessment, the placebo-
adjusted least squares mean (LSM)
HbA1c was further reduced by 0.36%
(95% CI 20.45 to 20.27) and 0.41%
(20.50 to 20.32) with sotagliflozin 200
and 400mg, respectively (both P, 0.001
vs. placebo). At 52 weeks, LSM differ-
ences from placebo remained significant:
20.25% (20.37 to 20.14; P , 0.001)
and20.31% (20.43 to20.20;P,0.001)
(Fig. 2A and Supplementary Table 2).
Approximately 19% of patients from
each group had an HbA1c ,7.0% at
baseline (Supplementary Table 1). Across
the entire study population, 22.8%,
36.9%, and 46.9% of the placebo, sotagli-
flozin 200 mg, and sotagliflozin 400 mg
groups achieved an HbA1c ,7.0% at
24 weeks, and at 52 weeks the propor-
tions were 20.9%, 30.0%, and 35.5%,
respectively. Among patients with a
baseline HbA1c $7.0% after 6 weeks
of insulin optimization, 15.7% of placebo-
treated patients, 27.2% of patients re-
ceiving sotagliflozin 200mg (P = 0.003 vs.
placebo), and 40.3% of patients receiv-
ing sotagliflozin 400 mg (P , 0.001)
achieved an HbA1c ,7.0% at week 24.
Within this subpopulation after 52 weeks,
18.4%, 27.7%, and 35.4% of patients
receiving placebo, sotagliflozin 200 mg,
and sotagliflozin 400 mg, respectively,
had an HbA1c ,7.0%.
Placebo-adjusted differences in FPG
were 20.55 mmol/L (29.8 mg/dL) (95%
CI 21.06 to 20.04 mmol/L; P = 0.034)
and20.99mmol/L (217.8mg/dL) (21.50
to 20.48; P , 0.001) for the 200 and
400 mg doses, respectively, at 24 weeks,
and 20.68 mmol/L (212.2 mg/dL)
(21.28 to 20.08; P = 0.028) and 21.08
mmol/L (219.4 mg/dL) (21.69 to20.47;
P , 0.001) at 52 weeks (Supplementary
Table 2).
The CGM substudy assessed glycemic
variability and included 136 patients
(Fig. 3 and Supplementary Table 3). Base-
line percent 6 SD of time in range
(3.9–10.0 mmol/L [70–180 mg/dL])
was 54.19% 6 12.94 and 53.18% 6
13.89 with placebo and sotagliflozin
400 mg, respectively, and time in range
increased by 10.4%6 2.89 (95% CI 4.68
to 16.12; P , 0.001), or 2.50 6 0.69 h,
with sotagliflozin 400 mg relative to
placebo. The placebo-adjusted decrease
in CGM SD was 0.37 6 0.17 mmol/L
(6.60 6 3.06 mg/dL) (95% CI 20.70
to 20.30 mmol/L; P = 0.033) with the
400 mg dose.
Insulin Dose
Total daily insulin dose in the placebo
group was within ;2% of baseline until
week 24, after which it increased. In both
sotagliflozin groups, after an initial de-
crease, insulin doses remained stable
after week 4 (Fig. 2B). At 24 weeks, the
LSM difference from placebo in bolus
Figure 2—Primary and other selected end points. Error bars represent SEM. A: LSM change from baseline in HbA1c over 52 weeks. Data between week
26 to week 0 depict arithmetic mean differences between screening and baseline HbA1c values to illustrate effect of insulin optimization. During
the 24-week double-blind (DB) core treatment (CT) period, HbA1c levels weremasked to study staff and an IDMC reviewed investigators’ insulin titration
decisions and provided feedback. During the 28-week double-blind extension (EXT), HbA1c was unmasked and the IDMC did not review insulin titration.
B: LSMpercent change frombaseline in total daily insulindose (TDD)over52weeks.C: LSMchange frombaseline inweightover52weeks.PBO,placebo.
insulin dosewas25.70% (95%CI212.82
to 1.42; P = 0.12) with sotagliflozin
200 mg and 212.67% (219.79 to
25.55; P , 0.001) with sotagliflozin 400
mg. Basal insulin dose increased with
placebo while decreasing modestly with
sotagliflozin (Supplementary Table 2 and
Supplementary Fig. 2A). At 52 weeks,
placebo-adjusted percent differences
in bolus insulin doses were 25.53%
(214.54 to 3.48; P = 0.23) with sotagli-
flozin 200 mg and 215.63% (224.67
to 26.59; P , 0.001) with sotagliflozin
400 mg. Absolute changes in insulin
doses appear in Supplementary Table 2
and Supplementary Fig. 2B.
Nonglycemic End Points
At baseline, mean BMI across all three
treatment groups was 29.66 6 5.387
kg/m2, and 44% of participants had a
BMI $30 kg/m2 (Supplementary Table
1). Decreases of 2.35 kg (95% CI22.85 to
21.85) and 3.14 kg (23.81 to 22.46)
occurred in the sotagliflozin 200 mg
group at 24 and 52 weeks, respectively.
At week 24, the LSM difference from
placebo with sotagliflozin 400 mg was
23.45 kg (23.95 to 22.94); at week
52 the difference was 24.32 kg (25.00
to23.64) (all P, 0.001 vs. placebo) (Fig. 2C
and Supplementary Table 2).
At week 12, sotagliflozin 200 and
400 mg were associated with placebo-
adjusted mean SBP reductions of
3.5 mmHg (95% CI 25.2 to 21.8; P ,
0.001) and 4.2mmHg (25.9 to22.4; P,
0.001), respectively. Diastolic bloodpres-
sure also decreased by 1.8 mmHg (22.8
to20.7; P = 0.001) and 1.9 mmHg (22.9
to 20.8; P , 0.001) with sotagliflozin
200 and 400 mg relative to placebo.
Figure 3—Sotagliflozin inTandem1 interstitial glucose. 24-h CGM tracing consisting of interstitial glucose readings collected every 5 min. Solid lines
represent mean values from each treatment group (light purple, placebo [n = 45]; light blue, sotagliflozin 200 mg [n = 44]; dark blue, sotagliflozin
400 mg [n = 47]); shaded areas represent6 1 SEM. The figure shows data collected from midnight. Actual start time for 24-h readings may vary for
each subject. Top of target CGM range = 10.0 mmol/L (180 mg/dL).
Figure 2dContinued.
Among those with SBP $130 mmHg at
baseline, sotagliflozin 200 and 400 mg
reduced SBP by 5.4 mmHg (29.9 to21.0;
P = 0.017) and 6.6 mmHg (210.9 to22.3;
P = 0.003) relative to placebo.
In the sotagliflozin 200 and 400 mg
arms, estimated glomerular filtration rate
initially decreased by 3 and 4 mL/min/
1.73 m2, respectively, then increased,
remaining ;2 mL/min/1.73 m2 below
baseline between weeks 24 and 52
(Supplementary Fig. 3 and Supplementary
Table 2). The reductions in estimated glo-
merular filtration rate were reversed 1
week after discontinuation of sotagliflozin
(Supplementary Table 2).
At the week 52 visit, mean total cho-
lesterol increased by 0.1 mmol/L in the
placebo group andby 0.2 and 0.3mmol/L
in the sotagliflozin 200 and 400 mg
groups, respectively. Mean LDL choles-
terol increasedby 0.1, 0.1, and 0.2mmol/L
with placebo, sotagliflozin 200 mg, and
sotagliflozin 400 mg, respectively. Other
lipid changes were small and not con-
sidered clinically meaningful.
Composite End Points
More patients receiving sotagliflozin
than placebo achieved composite end
points including an HbA1c,7.0% plus no
severe hypoglycemia, DKA, or weight
gain (Supplementary Fig. 4). The pro-
portion achieving an HbA1c ,7.0%
without experiencing any severe hypo-
glycemia or DKA at 24 weeks was 21.64%
with placebo, 33.46% with sotagliflozin
200 mg, and 43.51% with sotagliflozin
400 mg (Supplementary Fig. 5). The
differences from placebo were statisti-
cally significant and remained signifi-
cant at 52 weeks (sotagliflozin 200 mg:
7.21% [95%CI20.27 to 14.68;P =0.049];
sotagliflozin 400 mg: 13.41% [5.67
to 21.15; P , 0.001]). Throughout the
study, the difference in proportions of
placebo- and sotagliflozin-treated pa-
tients who achieved an HbA1c ,7.0%
and experienced either severe hypogly-
cemia (#3.0%) or DKA (#1.5%) was not
statistically significant (Supplementary
Fig. 5). Similar proportions of patients
in the sotagliflozin treatment groups
achieved an HbA1c reduction $0.5%
without severe hypoglycemia or DKA
(Supplementary Fig. 5).
The proportion of patients who
achieved an HbA1c ,7.0% without
weight gain at 24 weeks was 8.58%
with placebo, 30.42% with sotagliflozin
200 mg, and 43.51% with sotagliflozin
400 mg (Supplementary Fig. 6 and
Supplementary Table 4), with treatment
differences from placebo of 21.84% (95%
CI 14.97 to 28.71; P, 0.001) and 34.93%
(27.68 to 42.18; P , 0.001) for sotagli-
flozin 200 and 400 mg, respectively.
Significantly more patients who achieved
anHbA1c,7.0% lost.5%ofbodyweight
while taking sotagliflozin 200 mg (dif-
ference from placebo, 5.34% [1.89 to
8.78; P , 0.001]) or 400 mg (12.61%
[7.99 to 17.24; P , 0.001]), and few
sotagliflozin-treated patients gained weight
(Supplementary Fig. 6andSupplementary
Table 4). At 52 weeks, the proportions of
patients losing or not gaining weight
remained significantly larger in the
sotagliflozin groups, and similar patterns
were observed among those with an HbA1c
reduction $0.5% at 24 and 52 weeks
(Supplementary Fig. 6 and Supplementary
Table 4).
At 24 weeks, a composite outcome of
HbA1c ,7.0%, no weight gain, no severe
hypoglycemia, and no DKA was achieved
by 7.84%, 27.76%, and 40.84% of patients
receiving placebo, sotagliflozin 200 mg,
and sotagliflozin 400 mg, respectively.
Differences from placebo were 19.92%
(95% CI 13.25 to 26.59; P , 0.001) and
33.00% (25.86 to 40.15; P, 0.001) in the
sotagliflozin 200 and 400 mg groups,
respectively. Similar treatment differen-
ces were maintained at 52 weeks (Sup-
plementary Fig. 6 and Supplementary
Table 4).
Patient-Reported Outcomes
Treatment satisfaction measured by
the DTSQs remained stable in the pla-
cebo group while increasing in both
sotagliflozin groups. At week 24, the
LSM difference between placebo and
sotagliflozin 200 mg was 2.5 (95% CI
1.7 to 3.3) and between placebo and
sotagliflozin 400 mg was 2.5 (1.8 to 3.3),
changes that were statistically significant
and clinically meaningful (P , 0.001)
(Supplementary Table 2 and Supple-
mentary Fig. 7). Diabetes distress was
measured with the DDS2 throughout
the study and decreased significantly
in both sotagliflozin groups while in-
creasing with placebo (Supplementary
Table 2 and Supplementary Fig. 8). At
week 24, sotagliflozin-treated patient
scores on the DDS2 decreased by 0.7
(20.9 to20.4; P, 0.001) and 0.8 (21.0
to 20.5; P , 0.001) with the 200 and
400 mg doses, respectively, relative to
placebo. At week 52, LSM differences
from placebo were20.4 (20.7 to20.2;
P = 0.003) and20.5 (20.8 to20.2; P,
0.001) for sotagliflozin 200 and 400 mg,
respectively.
Hypoglycemia
Over 52 weeks, fewer patients receiving
sotagliflozin 200mg than those receiving
placebo reported documented hypo-
glycemia#3.9 mmol/L (#70 mg/dL) or
#3.0 mmol/L (#55 mg/dL), and the fre-
quency of documented hypoglycemia
was similar between the placebo and
sotagliflozin 400 mg groups (Table 1 and
Supplementary Table 2). Documented
hypoglycemia #3.9 mmol/L occurred
at frequencies of 96.1, 84.1, and 90.0
events per person-year in the placebo,
sotagliflozin 200 mg, and sotagliflozin
400mg groups, respectively, with relative
rates of 0.88 (95% CI 0.77 to 0.99; P =
0.040) for sotagliflozin 200 mg and 0.93
(0.82 to 1.06; P = 0.28) for sotagliflozin
400 mg versus placebo. The proportion
of patients with SMBG #3.0 mmol/L
from week 51 to 52 was 23.5%, 15.1%,
and 13.9% on placebo, sotagliflozin
200 mg, and sotagliflozin 400 mg, re-
spectively, with a relative risk for so-
tagliflozin 200 and 400 mg versus
placebo of 0.64 (0.44 to 0.93; P =
0.017) and 0.59 (0.40 to 0.87; P =
0.007), respectively.
Over52weeks, 17 (6.5%)patients from
each sotagliflozin group and 26 (9.7%)
placebo-treated patients experienced $1
positively adjudicated severe hypo-
glycemia event (Table 1). Two patients
receiving placebo and one receiving
sotagliflozin 200 mg discontinued due
to severe hypoglycemia.
DKA and Acidosis-Related Adverse
Events
Out of 82 patients reporting a serious
or nonserious acidosis-related event
(Supplementary Table 5), 21 had $1
positively adjudicated DKA event:
1 (0.4%; a CSII user) in the placebo group,
9 (3.4%; 8 CSII users) in the sotagliflozin
200mg group, and 11 (4.2%; 7 CSII users)
in the sotagliflozin 400 mg group. In
14 out of 21 DKA events, patients had
blood glucose .250 mg/dL (Supple-
mentary Table 5). Positively adjudi-
cated DKA led to discontinuations by
four patients in each sotagliflozin group
(Table 1).







Any adverse event 216 (80.6) 215 (81.7) 209 (79.8)
Serious adverse event 20 (7.5) 27 (10.3) 29 (11.1)
Severe adverse event 7 (2.6) 12 (4.6) 12 (4.6)
Death 1 (0.4)* 0 0
Positively adjudicated adverse events
$1 severe hypoglycemia event† 26 (9.7) 17 (6.5) 17 (6.5)
$1 severe nocturnal hypoglycemia event†** 10 (3.7) 10 (3.8) 2 (0.8)
$1 DKA event 1 (0.4) 9 (3.4) 11 (4.2)
$1 DKA event among CSII users 1/160 (0.6) 8/156 (5.1) 7/157 (4.5)
$1 DKA event among MDI users 0/108 1/107 (0.9) 4/105 (3.8)
Major adverse cardiovascular events
Myocardial infarction or hospitalization for
unstable angina 3 (1.1) 4 (1.5) 0
Stroke 1 (0.4) 0 1 (0.4)
Heart failure hospitalization 0 0 0
Coronary revascularization 2 (0.7) 2 (0.8) 0
Drug-induced liver injury 0 0 2 (0.8)
Events of special interest
Any 266 (99.3) 260 (98.9) 259 (98.9)
Genital mycotic infection 9 (3.4) 24 (9.1) 34 (13.0)
Diarrhea‡ 18 (6.7) 22 (8.4) 27 (10.3)
Urinary tract infection 19 (7.1) 26 (9.9) 11 (4.2)
Bone fracture 10 (3.7) 9 (3.4) 5 (1.9)
Renal event§ 5 (1.9) 7 (2.7) 4 (1.5)
Volume depletion|| 4 (1.5) 8 (3.0) 4 (1.5)
Malignancies of special interest¶ 0 2 (0.8) 2 (0.8)
Amputation 0 0 1 (0.4)
Pancreatitis 0 0 0
Venous thrombotic event 0 0 0
Any documented hypoglycemia# (SMBG #3.9 mmol/L
[#70 mg/dL]) 266 (99.3) 260 (98.9) 258 (98.5)
Any nocturnal documented hypoglycemia** 247 (92.2) 239 (90.9) 238 (90.8)
Any SMBG value #3.0 mmol/L (#55 mg/dL) 248 (92.5) 250 (95.1) 244 (93.1)
Any adverse event leading to discontinuation 11 (4.1) 13 (4.9) 17 (6.5)
Any event of special interest leading to discontinuation†† 7 (2.6) 8 (3.0) 12 (4.6)
Aortic valve incompetence 1 (0.4) 0 0
Diarrhea 1 (0.4) 0 1 (0.4)
Hepatitis 0 0 1 (0.4)
Urinary tract infection 0 1 (0.4) 0
Cystitis glandularis 1 (0.4) 0 0
Vulvovaginal events‡‡ 1 (0.4) 0 2 (0.8)
Blood creatinine increased 0 0 1 (0.4)
Hepatic enzymes increased 0 1 (0.4) 1 (0.4)
DKA (positively adjudicated) 0 4 (1.5) 4 (1.5)
Acetonemia§§ 0 1 (0.4) 1 (0.4)
Hypoglycemia 3 (1.1) 1 (0.4) 0
Severe hypoglycemia (positively adjudicated) 2 (0.7) 1 (0.4) 0
Data are n or n (%) and include patientswho received at least one dose of a study drug and include events that occurred up to 30 days after the last dose
of double-blind study treatment. *Death due to endocarditis, judged not related to study drug. †Severe hypoglycemia was defined as any
event that required assistance from another person or during which the patient lost consciousness or had a seizure. Hypoglycemia events include
all those that occurred between first and last dose of study drug during the 52-week double-blind treatment period. ‡Diarrhea was mostly
mild to moderate and transient. §Renal events are listed in Supplementary Data. ||Volume depletion events are listed in Supplementary Data.
¶Included two breast cancer cases, one thyroid cancer, and one melanoma. #Documented hypoglycemia was defined as a blood glucose level
of#3.9mmol/L (#70mg/dL)withorwithouthypoglycemia symptoms. In the sotagliflozindevelopmentprogram, hypoglycemia is consideredanevent
of special interest, with a specialized case report form. Because analysis for hypoglycemia was based on data recorded in the case report form,
investigators were asked to not submit hypoglycemic events on the adverse event case report form unless the episode met criteria for a serious
adverse event. **Nocturnal hypoglycemia was defined as positively adjudicated severe hypoglycemia or investigator-reported documented
hypoglycemia (blood glucose level of #3.9 mmol/L [#70 mg/dL] with or without hypoglycemia symptoms) that occurred between midnight
and 5:59 A.M., regardless of whether the patient was awake during the event. ††All events of special interest leading to discontinuation were
investigator reported except for DKA and severe hypoglycemia, which were positively adjudicated. ‡‡Vulvovaginal mycotic infection, vulvovaginits,
and vulvovaginal pruritus. §§Both cases of acetonemia were negatively adjudicated for DKA.
Mean BHB levels increased by ;0.1
mmol/L from baseline in both sotagli-
flozin groups (Supplementary Fig. 9).
Over 52 weeks, a BHB $0.6 mmol/L
occurred in 15.7%, 44.1%, and 45.8%
of patients in the placebo, sotagliflozin
200 mg, and sotagliflozin 400 mg groups,
respectively.
Other Safety Outcomes
As shown in Table 1, during 52 weeks of
double-blind treatment, the frequency of
overall adverse events was similar among
the treatment groups: 216 (80.6%),
215 (81.7%), and 209 (79.8%) with pla-
cebo, sotagliflozin 200 mg, and sotagli-
flozin 400 mg, respectively. The total
number of events of special interest
occurred at similar rates: 266 (99.3%),
260 (98.9%), and 259 (98.9%) with placebo,
sotagliflozin 200 mg, and sotagliflozin
400 mg, respectively. Sotagliflozin-
treated patients reported more serious
adverse events (placebo: 20 [7.5%];
200 mg: 27 [10.3%]; 400 mg: 29
[11.1%]), and severe adverse events
occurred in 7 (2.6%) placebo-treated
patients and 12 patients from each
sotagliflozin group (4.6%). One death
due to endocarditis occurred in the pla-
cebo group. In the sotagliflozin groups,
13 (4.9%; 200 mg) and 17 (6.5%; 400 mg)
patients discontinued due to an ad-
verse event, compared with 11 (4.1%)
taking placebo.
Adverse events were mostly mild to
moderate in severity. The most common
events of special interest were genital
mycotic infections (consistent with
SGLT2 inhibition) and diarrhea (consis-
tent with SGLT1 inhibition) (Table 1).
Among sotagliflozin-treated patients,
24 (9.1%; 200 mg) and 34 (13.0%;
400 mg) reported a genital mycotic in-
fection, compared with 9 (3.4%) receiv-
ing placebo. Three patients discontinued
due to vulvovaginal events (one receiving
placebo and two receiving sotagliflozin
400 mg). Diarrhea occurred in 18 (6.7%),
22 (8.4%), and 27 (10.3%), patients re-
ceivingplacebo, sotagliflozin200mg, and
sotagliflozin 400 mg, respectively, and
led to one discontinuation each in the
placebo and sotagliflozin 400 mg groups.
Bone fractures occurred in 10 (3.7%),
9 (3.4%), and 5 (1.9%) patients tak-
ing placebo, sotagliflozin 200 mg, and
sotagliflozin 400 mg, respectively. There
was one transmetatarsal amputation that
was considered to be not related to
the study drug in a patient taking sotagli-
flozin 400mgwho had a previous history
of foot and toe amputations. Four pa-
tients (two fromeach sotagliflozin group)
reported malignancies (two breast, one
thyroid, and one melanoma); none were
considered drug-related.
CONCLUSIONS
This study demonstrated the efficacy of
sotagliflozin in reducing HbA1c and im-
proving patient outcomes beyond HbA1c
(31). Sotagliflozin 400 mg was associated
with lower insulin doses, FPG, weight,
and SBP as well as improved glycemic
variability with less hypoglycemia.
Sotagliflozin 200 mg did not reduce bolus
insulin doses; however, reductions in
total insulin dose, FPG, and weight
were associated with P values ,0.05.
The incidence of severe hypoglycemia
was lower with sotagliflozin than pla-
cebo. DKA was increased with sotagli-
flozin treatment, yet significantly more
people taking sotagliflozin 200 or 400 mg
than those receiving placebo had an
HbA1c ,7.0% without experiencing se-
vere hypoglycemia, DKA, or weight gain
at 24 and 52 weeks. Those receiving
sotagliflozin also reported statistically
significant improvements in treatment
satisfaction and diabetes distress.
The glycemic and weight reductions,
as well as composite end points including
achievement of HbA1c targets without
severe hypoglycemia, DKA, or weight
gain, were comparable to observations
from the other inTandem trials. In the
24-week, global inTandem3 study,
sotagliflozin 400 mg yielded significant
placebo-adjusted reductions in HbA1c,
weight, insulin dose, and blood pressure
with reduced hypoglycemia and a low
incidence of DKA in patients with T1D
(14). In inTandem3, insulin doses were
not optimized prior to baseline, a key
difference from the current study. The
inTandem2 trial was conducted for
52 weeks in Europe with the same design
as this study and had similar overall
findings, including an even more pro-
nounced improvement in glycemic var-
iability (32). SGLT1 inhibition blunts and
delays postprandial glucose absorption.
In this and the other inTandem studies,
the unique benefit of this mechanism is
supported by a lower requirement for
bolus insulin, with associated reductions
in glycemic variability and hypoglycemia
relative to placebo.
Dapagliflozin Evaluation in Patients
with Inadequately Controlled Type 1 Di-
abetes (DEPICT-1) is a phase 3 trial eval-
uating the use of dapagliflozin in T1D.
BaselineHbA1cwas 8.5% (higher than the
inTandem1 baseline HbA1c) after an 8-
week lead-in period in which insulin treat-
ment was titrated to individual glucose
targets without optimizing it, and placebo-
adjusted HbA1c reductions were 0.4% to
0.5% (15). Patients with HbA1c ,7.5% at
baseline were excluded. In the current
study, 19% of patients had HbA1c ,7.0%
at randomization, and after 6 weeks of
insulin optimization, total mean 6 SD
baseline HbA1c was 7.6% 6 0.7. The
further HbA1c decrease at 24 weeks was
0.4%. Sotagliflozin 400 mg was also
associated with significantly improved
measures of glycemic variability, as have
been reported with dapagliflozin and can-
agliflozin (15,33). These improvements
were achieved with decreases in total
insulin doses that were driven by bolus
insulin doses at 24 weeks.
There are multiple pathophysiological
mechanisms by which SGLT2 inhibition
might increase ketosis, including basal
insulin reductions, glucagon increases,
and increased urinary glucose excretion,
all of which lead to a shift from glucose
to fat as source of energy and therefore
increase rates of lipolysis in adipose
tissue and ketogenesis in the liver, which
would increase circulating ketone body
levels (19,20). The rate of DKA in this
study was higher with sotagliflozin than
placebo but still within the range re-
ported in the general T1D population
(2). The majority of patients resumed
therapy after temporary discontinuation
of sotagliflozin due to a DKA event. When
using similar adjudication categories,
the DKA rates were consistent between
DEPICT-1 and this study (34). A contrib-
uting factormayhavebeenCSII use,which
can increase DKA risk through opera-
tional or mechanical failures (35,36).
CSII users comprised 60% of the total
study population and 75% of patients
reporting DKA in the sotagliflozin groups
(and the single placebo-treated patient
reporting DKA). A preponderance of DKA
among CSII users is consistent with other
studies of SGLT inhibitors in T1D (14,15).
In this and the other inTandem studies,
sotagliflozin was associated with mildly
increased mean BHB levels of;0.1 mmol/L
(the smallest increment detectable by
point-of-care BHB meters). Increased
efforts to mitigate DKA, including protocol
revisions, “Dear Dr.” letters, site training,
and improved educational materials (pa-
tient wallet cards; Supplementary Data),
were distributed after U.S. and European
regulatory authorities issued safety com-
munications about the risk of DKA with
SGLT2 inhibitors in 2015. This enhanced
risk mitigation strategy reduced the
severity of ketosis for several patients.
Further work needs to be done to elu-
cidate the risk factors for DKA and iden-
tify the characteristics of patients who
would be at higher risk. When SGLT
inhibitors are administered, monitoring
for ketosis, particularly during metabol-
ically stressful situations, is required.
SGLT inhibitors should be discontinued
before scheduled surgical procedures,
and patients and clinicians should remain
in close consultation regarding other
forms of behavioral and physiological
stress (37).
This study population had a mean
baseline BMI of 30 kg/m2 and nearly
half were obese, consistent with the gen-
eral adult population with T1D (2,3,38).
Sotagliflozin provided a dose-dependent
decrease in weight of 3–4 kg (4–5%)
relative to placebo, and the magnitude
of weight reductions increased through-
out the year-long study, demonstrating
that sotagliflozin maintained weight loss
even in patients receiving intensified in-
sulin therapy.
Sotagliflozin treatment improved di-
abetes distress and treatment satisfac-
tion in this study and inTandem2 (32).
Decreases in weight and/or insulin doses
may be linked to these improvements, as
suggested by studies reporting improved
treatment satisfaction with canagliflozin
and pramlintide used as adjunctive therapy
for T1D (33,39).
Generalization of these results is lim-
ited by protocol details including the
population recruited (HbA1c 7–11%), the
supervised insulin optimization efforts
during lead-in and for 52 weeks after
randomization, more frequent SMBG
and ketone testing than in clinical prac-
tice, and the expertise and attention
of the investigators and study staff. A
regulatory request that HbA1c and FPG
be masked until after the primary end
point assessment at week 24 also does not
reflect clinical practice. The patient educa-
tion and ketone monitoring called for in
the protocol (see details in Supplementary
Data) mitigated DKA risk, such that the
incidence in the placebo-treated arm was
0.4%. This level of DKA mitigation may be
difficult to achieve in clinical practice.
In conclusion, the addition of sotagliflozin
to intensified insulin therapy for 1 year
in patients with T1D reduced HbA1c
and improved clinical outcomes be-
yond HbA1c, including weight reduc-
tion, increased time in range, and a
lower incidence of severe hypoglycemia.
To date, advances in T1D management
have been largely limited to insulin
formulation and delivery innovations
(1,5,6). Although SGLT inhibition is asso-
ciated with DKA, this risk is manageable
with proper education and mitigation
plans. The beneficial effects on HbA1c,
glycemic variability, and weight with less
hypoglycemia outweigh this risk and
support the combination of SGLT inhib-
itors with insulin as a therapeutic ap-
proach for T1D (14–16,24,33,40). After
1 year, substantially greater proportions
of patients receiving sotagliflozin versus
placebo achieved HbA1c targets with-
out experiencing severe hypoglycemia,
DKA, or weight gain and had improve-
ments in treatment satisfaction. We con-
clude that sotagliflozin is effective in
subjects with T1D and has an acceptable
risk-benefit profile.
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